Currently, HER2 (ERBB2)-targeted antibody Trastuzumab is the only first-line option for GC’s targeted treatment (Van Cutsem et al. 2016); for immunotherapy, the response rate for PD-1/PD-L1-based regimens is limited in GC population, while the choice of immune checkpoint inhibitors’ combination with chemotherapy or targeted agents were controversial (Lordick and Janjigian 2016). Here, ERBB2 is linked to gastric cancer.